AKT1 and acute lymphoblastic leukemia: We clarified these puzzling findings by revealing that CIGB-300 can directly interact with the CK2α catalytic subunit of the enzyme and inhibit its activity in T-ALL cells, as demonstrated by the inhibition of Akt S129 phosphorylation, a surrogate marker for CK2 enzymatic activity in cells [21].